Concord Biotech jumps 8% on USFDA nod for Mycophenolate Mofetil oral suspension

Concord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the USFDA for its Mycophenolate Mofetil for Oral Suspension. This antimetabolite immunosuppressant is used in organ transplant patients.

Raccontata daeconomictimes.indiatimes.com